Latest AI and machine learning research in dementia for healthcare professionals.
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide. Conventional downstream interventions targeting β-amyloid (Aβ) and tau proteins have repeatedly failed in clinical practice, and mitochondrial functional decline has been identified as the core upstream driver of AD pathogenesis. Focusing on the mitochondrial functional network as the core target, this paper syste...
ETHNOPHARMACOLOGICAL RELEVANCE: The dried root of Paeonia lactiflora Pall. has a long history of medicinal use in traditional Chinese medicine. Classical materia medica and traditional practice describe Paeonia-related medicinal materials for headache, dizziness, restlessness, and other neurological or behavioral manifestations, particularly in disorders traditionally associated with blood or yin ...
Automated Alzheimer's disease (AD) classification from structural MRI typically employs either feature-engineered machine learning (ML) or end-to-end ...
Cerebrospinal fluid biomarkers, and more recently blood-based biomarkers, are playing a pivotal role in reshaping the clinical management of neurodege...
BackgroundMild Alzheimer's disease (AD) is associated with alterations in brain activity, which can be detected using electroencephalography (EEG). In...
INTRODUCTION: Digital language markers show promise in detecting early cognitive impairment related to Alzheimer's disease (AD), yet their relationshi...
INTRODUCTION: Brain-age gap (BAG), the difference between predicted age and chronological age, is studied as a biomarker for the natural progression o...
Caregiver-infant vocal interactions are foundational for early development, yet most evidence is derived from brief laboratory or home-visit observati...
Neuropsychiatric symptoms (NPS) are the most clinically consequential manifestations of dementia, yet they are frequently underestimated as secondary ...
INTRODUCTION: Apolipoprotein E (APOE) ε4 is the strongest genetic risk factor for late-onset Alzheimer's disease (AD), but its contribution to disease...
Artificial intelligence (AI) is rapidly entering dementia clinical practice, offering opportunities across the care continuum. However, cognitive decl...
BACKGROUND: Alzheimer's disease (AD), a neurodegenerative disorder, is pathologically defined by the accumulation of amyloid-β (Aβ) plaques, hyperphos...
BACKGROUND: Sudden Unexpected Death in Epilepsy (SUDEP) is a leading cause of epilepsy-related mortality, yet remains under-communicated in clinical p...
BACKGROUND AND PURPOSE: Choroid plexus volume (CPV) may reflect cognitive impairment and glymphatic dysfunction. However, its clinical use is limited ...
Alzheimer's disease (AD) and mild cognitive impairment (MCI) require accurate early diagnosis to support timely clinical intervention and disease mana...
Neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD), are multifactorial diseases that are characterized by sev...
Butyrylcholinesterase (BChE) plays a key role in preserving appropriate cholinergic neurotransmission that is essentially altered in the brains of adv...
BACKGROUND: Previous research links frailty to cognitive decline, but the relationship between frailty and motoric cognitive risk syndrome (MCR), a de...
Synaptic dysfunction is a major driver of cognitive decline in Alzheimer's disease (AD), yet its extent and molecular basis in the retina remain poorl...
Encephalitic alphaviruses such as Western equine encephalitis virus (WEEV) result in significant morbidity through acute viremia and postencephalitic ...